Email Updates

Search form

You are here

A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection

Include in
Published Research

Vaccinations were well tolerated with no serious adverse events but produced only modest augmentation of existing HIV-specific CD4+T cell responses, with little augmentation of CD8+ T cell responses. Compared with placebo, the vaccination regimen had no significant effect on the kinetics or magnitude of viral rebound after interruption of ART and no impact on the size of the HIV reservoir in the CD4+ T cell compartment.

December 6, 2017
Science Translational Medicine